Camrelizumab Plus Amlotinib and Chemotherapy in the First-line Treatment of Melanoma
Status:
Recruiting
Trial end date:
2023-08-14
Target enrollment:
Participant gender:
Summary
To evaluate the objective response rate of camrelizumab combined with anlotinib and
nab-paclitaxel in patients with untreated advanced mucosal melanoma.